Aptus Clinical, as the full service CRO provider for the Phase 1b/2a Cancer Appetite Recovery Study (CAReS), has assisted Artelo Biosciences in the planning and running of this important study which investigates the potential for ART27.13 (a peripherally synthetic cannabinoid agonist), to alleviate anorexia associated with cancer, a condition with significant unmet need and no licensed treatments.
Steve McConchie, CEO at Aptus Clinical, said ‘The CAReS study is an important investigation in cancer anorexia, and we are delighted that the partnership we have developed with Artelo has achieved the important milestone of first patient recruited and dosed. We are excited to be working with Artelo in assessing whether ART27.13 can make a difference to patients who are suffering from this distressing condition and improve their quality of life.
Gregory D. Gorgas, President and CEO of Artelo Biosciences, commented “Artelo are excited to be starting the CAReS trial investigating ART27.13 in patients who currently have no licensed options to alleviate the devastating condition of cancer-associated anorexia. ART27.13 has already demonstrated significant weight gain potential in patients with chronic back pain who were otherwise healthy, and we look forward to seeing the results when translated into anorexic cancer patients who have suffered significant weight loss.”
For further information on the CAReS study please visit https://ir.artelobio.com/news-events/press-releases/detail/60/artelo-biosciences-doses-first-patient-in-cares-study-with or https://www.isrctn.com/ISRCTN15607817
About Aptus Clinical
Aptus Clinical is a clinical contract research organisation that specialises in the design, conduct and delivery of early phase clinical studies with a particular focus in oncology, rare diseases, cell and gene therapies. Projects are delivered by a team of highly experienced drug development experts utilising their extensive network of academic links. Aptus Clinical aims to partner with clients to help them transform their promising molecules into valued medicines.
About Artelo Biosciences
Artelo Biosciences, Inc. is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting endogenous signaling pathways including the endocannabinoid system. Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, PTSD, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio.
About ART27.13
ART27.13 is a highly potent, peripherally restricted synthetic, dual GPCR agonist believed to target the cannabinoid receptors CB1/CB2, which has the potential to increase appetite and food intake. Originally developed by AstraZeneca plc, ART27.13 has been in five Phase 1 clinical studies including over 200 subjects where it demonstrated a statistically significant and dose-dependent increase in body weight in healthy subjects. Importantly, the changes in body weight were not associated with fluid retention and the distribution of the drug enables systemic metabolic effects while minimising central nervous system mediated toxicity. Artelo is advancing ART27.13 as a supportive care therapy for cancer patients suffering from anorexia and weight loss where the current annual global market is estimated to be valued in excess of $2 billion.
